L
LeeYun Bio Science
Bio-pharmaceutical research for chronic skin diseases
About LeeYun Bio Science
LeeYun Bio Co., Ltd. is a South Korean biopharmaceutical research company founded in 2020 by co-representatives Jin-hee Lee and Jeong-in Yoon. The company's headquarters are located in the Chungnam National University Startup Support Center in Daejeon, with its research institute situated at the Korea Research Institute of Chemical Technology. LeeYun Bio focuses on developing solutions for chronic skin diseases by researching and creating bioactive substances to alleviate skin pruritus (itchiness) and inflammation.
The firm's core competency lies in its medicinal synthesis technology, which designs small molecule drugs that can act directly within cells. This enables the construction of a chemical library specialized in suppressing skin inflammation, itching, and pain, leading to the development of various medicinal products and functional material ingredients. LeeYun Bio develops functional biomaterials for both human and veterinary dermatological applications, with a platform centered on organic synthesis-based compounds that serve as steroid alternatives. The company aims to provide non-steroidal treatments that reduce skin irritation and inflammation.
LeeYun Bio has developed its own patented ingredient, APN-Flavo-02, which is featured in its 'LeeYun Repair Lotion'. This product is a moisturizing lotion formulated for sensitive skin conditions such as atopic dermatitis, itchiness, and severe dryness. Clinical tests have reportedly shown it to be non-irritating. The lotion also contains anti-inflammatory ingredients like Houttuynia Cordata, Centella Asiatica, and Propolis. The company markets its products under several brand names, including LeeYun, a high-functioning cosmeceutical brand for sensitive skin, and Foret.A, which focuses on nature-friendly ingredients.
The company is venture capital-backed, having received funding from the Tech Incubator Program for Startup and Kingospring. As of November 2024, it completed an accelerator/incubator funding round.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Drug Development, Dermatology, Inflammatory Diseases, Chronic Disease, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2024 | $15M | $59M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for LeeYun Bio Science is 2K monthly website visits, up 53.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
LeeYun Bio Science in the Daejeon ecosystem
The LeeYun Bio Science office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about LeeYun Bio Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LeeYun Bio Science’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








